The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.

Keywords:
Melanoma, eye, Melanoma, conjunctiva, Brachytherapy, Enucleation
1.
Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, Shields JA: Conjunctival tumors: review of clinical features, risk, biomarkers, and outcomes – the 2017 J. Donald M. Gass lecture. Asia Pac J Ophthalmol 2017; 6: 109–120.
2.
Savar A, Esmaeli B, Ho H, Liu S, Prieto VG: Conjunctival melanoma: local-regional control rates, and impact of high-risk histopathologic features. J Cutan Pathol 2011; 38: 18–24.
3.
Dzwonczyk AM, Corrêa ZM, Augsburger JJ, Kulwin D: Eye-preserving treatment for invasive conjunctival melanoma. JAMA Ophthalmol 2014; 132: 1486–1488.
4.
Kim EC, Kim MS, Kang NY: Excision with corneoscleral lamellar keratoplasty and amniotic membrane transplantation of a corneal displaced recurrent conjunctival melanoma. Korean J Ophthalmol 2012; 26: 383–387.
5.
Mendoza PR, Grossniklaus HE: Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence? Int Ophthalmol Clin 2015; 55: 123–136.
6.
Vora GK, Demirci H, Marr B, Mruthyunjaya P: Advances in the management of conjunctival melanoma. Surv Ophthalmol 2017; 62: 26–42.
7.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522–530.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.